Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a sell rating to a hold rating in a report released on Wednesday.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

Actinium Pharmaceuticals Stock Up 2.0 %

NYSE:ATNM opened at $1.52 on Wednesday. The firm’s fifty day simple moving average is $1.27 and its 200-day simple moving average is $1.44. The stock has a market cap of $47.42 million, a PE ratio of -1.09 and a beta of 0.10. Actinium Pharmaceuticals has a fifty-two week low of $1.03 and a fifty-two week high of $10.24.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ATNM. Wellington Management Group LLP purchased a new position in Actinium Pharmaceuticals during the third quarter worth $112,000. XTX Topco Ltd acquired a new position in Actinium Pharmaceuticals in the third quarter valued at $268,000. Barclays PLC lifted its position in Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after buying an additional 32,784 shares during the period. Geode Capital Management LLC boosted its stake in Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after buying an additional 19,843 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new stake in Actinium Pharmaceuticals in the 4th quarter valued at about $32,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).